Greenhouse Funds LLLP Increases Stock Position in Phreesia, Inc. (NYSE:PHR)

Greenhouse Funds LLLP lifted its position in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 27.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,873,892 shares of the company's stock after buying an additional 626,579 shares during the quarter. Phreesia comprises about 3.0% of Greenhouse Funds LLLP's holdings, making the stock its 18th largest position. Greenhouse Funds LLLP owned 4.94% of Phreesia worth $72,307,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Invesco Ltd. lifted its position in Phreesia by 0.9% in the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company's stock valued at $1,013,000 after acquiring an additional 357 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Phreesia by 12.1% in the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock valued at $107,000 after purchasing an additional 459 shares in the last quarter. R Squared Ltd bought a new position in shares of Phreesia in the fourth quarter valued at approximately $30,000. BankPlus Trust Department purchased a new position in shares of Phreesia during the fourth quarter valued at approximately $34,000. Finally, Swiss National Bank grew its holdings in Phreesia by 1.3% during the fourth quarter. Swiss National Bank now owns 107,900 shares of the company's stock worth $2,715,000 after buying an additional 1,400 shares in the last quarter. Institutional investors own 92.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on PHR. KeyCorp cut their price objective on shares of Phreesia from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Piper Sandler restated an "overweight" rating and set a $33.00 price target (up from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and issued a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. DA Davidson cut their target price on Phreesia from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, Citigroup upped their target price on Phreesia from $31.00 to $35.00 and gave the company a "buy" rating in a report on Friday, January 10th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has a consensus rating of "Buy" and an average price target of $31.33.

Phreesia Stock Performance

NYSE:PHR traded up $0.14 during trading hours on Friday, reaching $24.73. The stock had a trading volume of 268,854 shares, compared to its average volume of 432,544. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a 50 day simple moving average of $25.62 and a 200 day simple moving average of $24.34. The stock has a market cap of $1.45 billion, a P/E ratio of -16.82 and a beta of 0.82.

Insider Buying and Selling

In other Phreesia news, General Counsel Allison C. Hoffman sold 1,213 shares of the business's stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $23.81, for a total transaction of $28,881.53. Following the sale, the general counsel now owns 137,921 shares of the company's stock, valued at $3,283,899.01. The trade was a 0.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Balaji Gandhi sold 4,813 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $132,261.24. Following the sale, the chief financial officer now owns 144,933 shares in the company, valued at approximately $3,982,758.84. This represents a 3.21 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 146,930 shares of company stock valued at $4,067,102. 5.80% of the stock is owned by insiders.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.